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ABSTRACT
Aims: To determine whether impairment of the executive functioning domain of cognition
could be detected by a battery of simple bedside cognitive tests of executive function
associated with inadequate glycaemic control.
Methods: People with type 2 diabetes attending a tertiary referral diabetic clinic who
consented to participate in the study underwent a brief battery of cognitive testing (the
Bedside Executive Screening Test) designed to detect executive function impairment.
Glycaemic control was determined using glycated haemoglobin levels (HbA1c). Inadequate
glycaemic control was defined as HbA1c ≥ 7.0%.
Results: Executive function impairment was detected in 51 (52%) of the 98 study
participants. The presence of executive function impairment was significantly associated
with poor glycaemic control (HbA1c ≥ 7.0%) (odds ratio 4.9, 95% confidence interval 1.3 –
18.8, p=0.019). There were no significant differences between patients with and without
executive function impairment with regard to age, target organ damage, patient reported
adherence, and hypoglycaemic therapy. Patients with a lower level of education were more
likely to demonstrate executive impairment when glycaemic control was poor (p=0.013).
Conclusion: Executive function impairment is common in a population of people with
difficult-to-manage type 2 diabetes. The presence of executive impairment is significantly
associated with poor glycaemic control.
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11. INTRODUCTION
1.1 EXECUTIVE FUNCTION
1.1.1 DEFINITION
The Diagnostic and Statistical Manuel of Mental Disorders, 4th edition, defines executive
function as one’s ability to plan, initiate, sequence, monitor and inhibit complex behaviour 1.
Executive function falls within the domains of cognition. It forms its own separate category
alongside other more well known domains, such as language, attention, memory and
visuospatial planning 2.
Executive functions comprise a set of skills responsible for orchestrating complex goal
directed activities such as finances, medications, transportation, shopping, cooking,
housework and using communication devices. These activities constitute the Instrumental
Activities of Daily Living (IADLs).
These activities are made possible through successful planning, initiation, sequencing with
ongoing monitoring and assessment for possible adjustments of goals or actions2,3.
Similarly to other cognitive functions, such as language and memory, these are acquired
skills. Intact executive functions are thus vital to human autonomy2.
Anatomically, the pre-frontal cortex and its basal ganglia connections are responsible for
executive functioning2. It is however difficult to localise specific executive functions to
specific areas within the frontal cortex3. The frontal cortex is connected to the caudate,
putamen, pallidum and thalamus via circuits. These connections are dynamically balanced
direct and indirect circuits2. The importance of these connections is manifested by the fact
2that executive impairment may occur without direct frontal damage i.e. via disruption of
these circuits2.
External sensory information (motivational, emotional, somatosensory) is integrated and
translated into goal directed behaviour. This relies on intact frontal lobe higher functions
(i.e. insight, judgement and abstraction) along with their connections to the systems they
control, allowing for execution of directed actions2.
Isolated executive impairment falls within the category of “mild cognitive impairment”. Mild
cognitive impairment being that which does not meet the criteria for dementia and thus by
nature a heterogeneous group of disorders4. In 1994 executive impairment was added to
the definition of dementia by the American Psychiatric Association5.
1.1.2 MEASURES OF EXECUTIVE FUNCTION
Executive functioning can be assessed using internationally accepted tools. These tools
score patients (using standardised norms) on their ability to carry out tasks that utilise the
executive domain. However there is no one single gold standard test, and so batteries of
tests are rather employed. Batteries often prove to be labour intensive to both the clinician
and patient and are often very time consuming2. Traditional cognitive screening tools are
generally insensitive to executive impairments and deficient in executive components6. The
mini mental state examination(MMSE) considered a measure of ‘global’ cognitive ability,
and probably the most commonly employed cognitive screening tool, contains no
components specifically addressed to executive functioning3. Patients with clear executive
impairment as detected by other specific executive screens have often been found to score
3within the normal range on the MMSE7. The MMSE was also found to be significantly
affected by socioeconomic status8.
Some of the well accepted screening tools or measures of executive function include: clock
drawing tasks, verbal fluency, the executive interview (EXIT25), Wisconsin card sorting test
and Trail making B component of the trail making tests.
Ideal cognitive screening tests should meet the following criteria:
- quick to administer (under two minutes), this helps gain acceptability amongst clinicians
- well tolerated and accepted by patients
- easy to score
- relatively independent of culture, language and education
- good inter-rater reliability
- both high sensitivity and specificity
- concurrent validity(correlate with other screening tools)6.
CLOCK DRAWING TASKS
Clock drawing tasks meet the above stated criteria. In particular they are quick and easy to
administer, easy to score with a good inter-rater reliability as well as having high patient and
clinician acceptability. 93% of surveyed physicians said they would use it6. Clock drawing
tests have been found to be less influenced by socioeconomic status than the MMSE8. They
also correlate well with other more traditional tests9. They were also found to have a
sensitivity of 91% and specificity of 95% in predicting future dementia10, and a sensitivity of
77% and specificity of 87% in detecting moderate cognitive impairment (MMSE specificity
496% but sensitivity only 66%). This is comparable to other well accepted screening tools i.e.
mammography for breast cancer11,12. Clock drawing tests have an acceptable sensitivity as a
first level screening tool, however they are probably not adequate as a stand-alone
screening tool owing to the high rate of false positives11.
Clock drawing tasks utilise many different skills, namely:-
- auditory comprehension
- visual memory
- planning
- abstract thinking
- motor programming and execution
- concentration6.
These tasks require the patient to plan, initiate a drawing and continue through a sequence
of constructional actions (i.e. drawing an outer circle, placement of numbers usually 12, 3, 6,
and 9 first and lastly placing the hands). The patient must be able to monitor progress and
implement corrections as the need arises9.
The CLOX1 is the first component of a two part clock drawing task. This first component is
specifically designed to detect executive impairment and discriminate it from other non-
executive failures such as constructional failure. Whereas the second part (CLOX2) is a
copying task much the same as the pentagon illustration used in the MMSE and correlates
with posterior cortical defects9.
5CLOX1 is scored out of 15, a score of 10 correlates with 2 standard deviations below the
mean9. Another attraction of clock drawing is that it offers a visual performance indicator
rather than just a numerical score13.
Table 1. Scoring system for the Executive clock drawing (CLOX) test9.
VERBAL FLUENCY MEASURES
Verbal fluency is a measure of temporal lobe (ability to create word clusters), frontal lobe
(ability to shift between clusters) and caudate nucleus function14.
Two measures commonly clinically employed include:
1. Phonemic verbal fluency, the patient is required to generate as many words as
possible within a given time period (one minute) beginning with a specific letter of
the alphabet F, then A, and finally S14.
62. Semantic verbal fluency makes use of categories, patients name as many objects
falling within the category, again within a certain time period (usually one minute)
i.e. animals, fruits and cities. Animals being the most frequently used category14.
There are established age and education appropriate norms for the different categories.
Age, education and gender influence scores15. Final levels of verbal fluency are usually
attained by age 12 years14.
THE EXIT25
This screening tool forms a short battery comprising 25 tasks, all reflecting frontal measures,
and takes around 15 minutes to administer. The EXIT25 requires formal training to
administer. It has been shown to correlate well with the CLOX1, the Wisconsin card sort test
and Trail making part B, two other measures of executive control function9. Patients are
scored from 0-50, higher scores correlate with worse impairment, with scores above 15
indicating significant impairment, correlating with a CLOX1 score of less than 10. The EXIT25
has been found to correlate well with verbal fluency16.
THE MINI-COG
This test combines two simple tasks, 3 item word recall testing episodic memory and a clock
drawing task. It has been found to be practical and effective as a screening tool for
dementia in large populations at risk17. It is not influenced by language or education. The
time taken to administer the mini-cog is roughly a quarter of that taken to administer the
MMSE13.
7Figure 1: Mini-Cog scoring algorithm13
1.1.3 IMPACT OF EXECUTIVE IMPAIRMENT ON THE INDIVIDUAL
Executive impairment has been shown to be strongly associated with several chronic
medical diseases1,2,5. More commonly associated conditions include schizophrenia, major
depressive disorders, chronic obstructive airways disease, sleep apnoea, congestive cardiac
failure, infection with Human Immunodeficiency Virus, renal failure, lung cancers,
hypertension, subcortical ischaemic vascular disease, pituitary tumours and type 2 diabetes
mellitus1,2,5.
During the normal aging process deterioration of executive function correlates with
longitudinal decline in functional status, and thus may be considered a predictor of
functional status. This was illustrated in the Freedom House Study5. In patients with chronic
diseases it may be viewed as a predictor of severity and disability2.
8Tests of executive function correlate strongly with instrumental activities of daily living
(IADL’s) rather than physical activities of daily living. Measures of executive function
(i.e.CLOX1 or EXIT25) prove a more reliable predictor of IADL’s in both healthy and impaired
individuals than measures of other cognitive function domains1,5,18. Executive functioning is
able to discriminate between independent patients, patients requiring moderate level
supervision and those requiring full supervision1.
Self-management is regarded as a set of skilled behaviours used to manage one’s illness.
This places a great responsibility on the individual8.
Executive impairment impacts negatively on a patients’ ability to self-manage their
disease19. It hinders their ability to comply with treatment regimens and implement
necessary lifestyle changes1,19. These patients have also been found to be more resistant
towards care and suffer from impaired medical-decision-making capacity1. Patients in
retirement communities were less likely to make use of newly introduced prosthetics in the
presence of executive impairment, demonstrating an inability to adopt new assistive
devices/practices2.
Dysfunction of the executive domain may be clinically evident if:2
1. The patient does not remember what is important
2. The patient cannot get to where they want to go
3. The patient cannot make appropriate decisions
4. The patient cannot complete tasks that he or she starts
5. The patient does not comply with therapy
9Patients with executive impairment are less likely to self-report their impairment/difficulty
than those with memory impairment, and more frequently may actually report it as memory
loss rather than executive dysfunction1,12. However impaired executive function may have a
more profound effect on ones autonomy than impaired memory1,2.
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1.2 TYPE 2 DIABETES MELLITUS AND COGNITION
1.2.1 DEFINITION
Diabetes mellitus refers to several disorders of abnormal carbohydrate metabolism, all
characterized by hyperglycaemia. Type 2 diabetes mellitus is associated with a relative
impairment in insulin secretion coupled with varying degrees of peripheral resistance to the
action of insulin20. Type 2 diabetes may also be considered a syndrome with multiple
associated co-morbidities and complications21. The associated insulin resistant state of type
2 diabetes is fundamental to the pathogenesis of the metabolic syndrome 19.
1.2.2 PREVALENCE
Type 2 diabetes mellitus accounts for approximately 90% of all cases of diabetes
worldwide22. There is an overall 4.5% prevalence with an estimated 1,283,400 people 1n
2010 suffering from type 2 diabetes in South Africa as published by the International
Diabetes Federation in 200923.
Dementia (all causes) has an incidence of 6.5% in those older than 65 years. Of this 4.4% is
attributable to Alzheimer’s disease, 1.6% vascular dementia and all other forms accounting
for the remainder 0.4%19. This underestimates the incidence of mild cognitive impairment
(MCI) which is generally not defined in epidemiologic studies.
The increasing number of diabetic and dementia patients will be compounded by a
generally ageing population worldwide24.
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1.2.3 DIAGNOSIS OF TYPE 2 DIABETES MELLITUS
Table 2: Society for Endocrinology, Metabolism and Diabetes of South Africa: Diagnostic
Criteria for Diabetes Mellitus25
1.2.4 GLYCATED HEAMOGLOBIN
Glycation occurs throughout the 120 day lifespan of the red blood cell. Of this fifty percent
occurs in days 90-120. Glycated haemoglobin (HbA1c) has been established as the
monitoring tool of choice when assessing medium term diabetic control26.
Target HbA1c levels differ between international organisations. However levels below 7%
are accepted for type 2 diabetics by the:
- American Diabetes Association
- UK National service framework for diabetes mellitus
- Society for Endocrinology, Metabolism and Diabetes of South Africa25,26.
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HbA1c levels above 7% have been shown to yield a four-fold greater risk for age related mild
cognitive impairment. A significant association persisted even when previously diagnosed
diabetics were excluded27. For every 1% increase in HbA1c there is an associated 40%
increase in age-related risk of developing mild cognitive impairment, especially when the
HbA1c above 7%27.
1.2.5 IMPACT OF TYPE 2 DIABETES ON COGNITION
Diabetes mellitus is recognised to be associated with cognitive dysfunction and cognitive
abnormalities28. Neuropsychological tests have demonstrated deficits in various aspects of
cognition in both young and elderly diabetics. Deficits affect global cognition, psychomotor
efficiency, episodic memory, semantic memory and working memory12. Cognitive
decrements may occur at two separate intervals of cognitive vulnerability:
1. Firstly occurring during brain development, ages 5-7 years, typically this would refer
to type 1 diabetes.
2. Later on they may develop within the neurodegenerative phase, generally from age
65 years onwards. This would be accounted for in the majority by type 2 diabetes.
Outside of these two periods it would need to occur in the face of both microvascular and
macrovascular target organ damage27.
Diabetes mellitus is a risk factor for neurological conditions of ageing, these include all
forms of dementia and cognitive decline22. The impact of diabetes mellitus on cognition has
been of interest for at least eighty years. It was first explored by Miles and Root who
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demonstrated impaired memory, poor mental arithmetic, and slowed psychomotor
efficiency in type 1 diabetics exclusively. They hypothesized that the main underlying
mechanism might be recurrent hypoglycaemic episodes. However this was disputed when
later cognitive impairment was also significantly associated with type 2 diabetics, in whom
chronic hyperglycaemia was thought to be responsible19.
The more typical pattern of cognitive deficits in diabetics is suggestive of frontal sub-cortical
dysfunction from a microvascular insult29. Structural brain imaging studies in type 2
diabetics between ages 60 to 65 years revealed an increase in both cerebral atrophy and
lacunar infarcts (OR 1.3-2.2)28. This pattern of microvascular disease of the brain is
characteristically associated with cardiovascular risk factors. In particular this frontal sub-
cortical syndrome manifests with significant executive impairment, motor slowing and
mood symptoms, with minimal memory loss29. These deficits impact on the individuals’
ability to plan, organize, problem solve, reason and also limits their insight12.
Longitudinal and population based studies have implicated type 2 diabetes mellitus as a risk
factor for age related cognitive decline and dementia28. Cognitive impairments have been
evidenced in multiple cross-section, longitudinal, and prospective studies8,19,21,22,24,29,30,31.
The Rotterdam study (cross-sectional study using dementia as a variable) showed a
significant association between diabetes mellitus and dementia, with the strongest
association for vascular pattern dementia. Importantly this was found to be independent of
education, body mass index, atherosclerosis, smoking, blood pressure or the use of anti-
hypertensive agents. It was also not explained by cerebral infarcts19. The Hisayama Study
(seven year follow-up of 828 diabetic residents aged 65 years and over without baseline
dementia) demonstrated an increased risk of vascular dementia19.
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In a cross-sectional population based study of home bound individuals diabetics had a worse
MMSE score: 24/30 vs 25.7/30. Only 50% of diabetic individuals successfully reproduced the
pentagon illustration whereas 68% of non-diabetics were successful. However more
sensitive tests of executive function such as the Trail B demonstrated significantly worse
scores for diabetics29. In a large cohort (10963 patients assessed at two separate occasions
six years apart) those with diabetes at baseline had a greater decline in scores on two
separate executive measures: digit symbol subset and first-letter word fluency. This
persisted after controlling for demographic and vascular risk factors, and was also
demonstrated when restricted to a younger age group of 47-57 years19. In a literature
review by Stewart et al. a strong association between poor verbal fluency scores and type 2
diabetes mellitus was demonstrated30.
1.2.6 POSSIBLE MECHANISMS OF IMPAIRED COGNITION
Mechanisms responsible for impaired cognition in the diabetic patient include both the
direct effects of diabetes mellitus itself as well as the indirect effects of associated co-
morbidities, medications used and/or diabetic complications27. Each patient is exposed to at
least one or more of these variables28. Different hypothesis include sub-cortical vascular
ischaemia, polypharmacy, hypoglycaemia and concurrent depression2. Evidence of
structural brain abnormalities has also been identified. Both silent and symptomatic infarcts
are seen with increased incidence on magnetic resonance imaging in diabetics. Imaging also
reveals a slight degree of cortical and sub-cortical atrophy in a generalised pattern. At
autopsy type 2 diabetics have an increased number of macroscopic infarcts24.
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1.2.6.1 DIRECT EFFECTS
There are several biological mechanisms that have been associated with impaired glucose
regulation and dementia27.
HYPOGLYCAEMIA
Hypoglycaemia seems to only be relevant in the acute setting, where it is associated with a
poorer cognitive ability, but not with any long term effects19,30,31. This would seem true as
there has been no association proven with more intensive treatment regimens which often
have a higher incidence of hypoglycaemic episodes19,30.
HYPERGLYCAEMIA
Toxic effects of hyperglycaemia have been thought to slowly cause progressive structural
and functional abnormalities in the brain24. Cognitive decline has been associated with
clinical markers of hyperglycaemia, i.e. use of hypoglycaemics, increased duration of
diabetes mellitus and diabetic complications31. Non-diabetic patients with hyperglycaemia
(patients with poor glucose tolerance or impaired fasting glucose) have been shown to score
poorly on cognitive testing31. A population based study found an increased rate of errors on
the MMSE performed by type 2 diabetic patients with higher fasting glucose levels30.
Pelmuter et al associated higher HbA1c readings with poorer word memory30.
States of chronic hyperglycaemia are associated with increased oxidative stress22. There is
direct neuronal damage from advanced glycation end products (AGES), a process similar to
those implicated in peripheral neuropathy22,27,30. AGES impairs vascular reactivity and thus
predisposes to subtle perfusion abnormalities19. Chronic exposure to hyperglycaemia may
cause abnormalities in cerebral capillaries i.e. basement membrane thickening and thus lead
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to microvascular changes predisposing to insidious ischaemia24. Hyperglycaemia may also
exacerbate areas of existing sub-clinical ischaemia via increased anaerobic metabolism and
acidotoxicity30.
HYPERINSULINAEMIA
Type 2 diabetes mellitus is initially associated with a state of hyperinsulinaemia. Insulin
appears to modulate cognition28. There are an abundance of insulin receptors in the brain,
insulin is able to actively cross the blood-brain-barrier and is also locally produced within the
brain24. It has been hypothesized that the increased levels of insulin circulating may be
directly responsible, or may serve as a marker of hypofunction of insulin degrading enzyme.
This enzyme is also involved in the metabolism of beta-amyloid, which is found in increased
amounts in the beta-islet cells of type 2 diabetics19. Beta-amyloid is found in patients with
Alzheimer’s disease at autopsy24,27,28. Insulin is believed to have vasoactive properties and
perhaps alters cognition through a vascular mechanism24.
Large population based studies have proven a significant association between MMSE
impairment in those with hyperinsulinaemia, this persisted after adjusting for cardiovascular
disease and other cardiovascular risk factors19.
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1.2.6.2 INDIRECT EFFECTS
Type 2 diabetes mellitus may be considered a complex with numerous disease related
factors rather than just a disease. This complex is associated with multiple co-morbidities
(hypertension, dyslipidaemia, obesity), chronic complications and treatment related
effects28. These may be considered as vascular and non-vascular mediated30. Stroke and
vascular co-morbidities are established risk factors for dementia in diabetic patients. Type 2
diabetes is itself a known risk factor for stroke, this risk again being both directly due to the
diabetes and indirectly secondary to the associated co-morbidities24. Several studies of non-
diabetic patients with hyperinsulinaemia have reported an increased risk of stroke. The
cortical-basal ganglia connections are dopaminergic mediated and very sensitive to
hypoperfusion and hypoxia1.
ATHEROSCLEROSIS
Type 2 diabetes mellitus is associated with hypercholesterolaemia or atherogenic
dyslipidaemia. This is a pro-thrombotic state24. In the Rotterdam study all indicators of
atherosclerosis were associated with dementia, vascular dementia being the most
prominent19. A large population study demonstrated an association between
hypertriglyceridaemia in diabetic patients and worse performance on cognitive testing
affecting attention, concentration, psychomotor speed and verbal fluency. These findings
were independent of glycaemic control, total cholesterol levels and blood pressure. These
effects were felt to be secondary to atherosclerotic disease itself as well as changes in blood
viscosity30.
18
HYPERTENSION
There is a well recognised strong relationship between type 2 diabetes and hypertension.
Effects of the hypertension itself are felt to be the cause of poorer cognition rather than
medication side-effects. This is demonstrated by the finding that patients on anti-
hypertensive treatment show little evidence of cognitive decline. The exception would be
treatment induced hypotension in elderly patients30. In a study by Kungsholmen
hypertension (systolic blood pressure greater than or equal to 180) interacted with diabetes
to increase the relative risk of any dementia, particularly vascular dementia24.
OTHERS
-The Apolipoprotien E (ApoE) allele is a risk factor for dementia29. When combined with
vascular risk factors such as hyperglycaemia it may interact to increase risks above those
associated with the traditional ApoE phenotype. This was shown in the Canadian study of
Health and Ageing19.
- Other associated co-morbid conditions may impact negatively on cognitive function10,24.
One example is depression, with a higher incidence of depression in diabetic patients this
may act as confounder or even exacerbator31. Diabetic patients with depression have more
cognitive symptoms and poorer diabetic control19. Obesity is another important associated
condition. Obese individuals are subject to increased risk of stroke. Obesity is also
frequently associated with obstructive sleep apnoea which also increases risk of stroke and
cognitive decline1,30.
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Figure 1: Pathophysiological mechanisms linking diabetes in the brain and dementia24
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2. THE STUDY
2.1 RATIONALE FOR STUDY
Adequate cognition particularly executive function is shown to be vital in disease self-
management, traditionally upon which diabetes relies heavily. Patients are required to
institute lifestyle changes, comply with behavioural and pharmacological interventions
aimed at managing their glycaemia, lipid profiles and frequently concomitant hypertension.
Patients with Type 2 diabetes are routinely screened for both microvascular and
macrovascular complications. This study explores the role of cognitive screening in patients
attending a Type 2 Diabetic clinic.
2.2 TOOL SELECTION
There is presently no single gold standard test for executive function2. Rather batteries of
neuropsychological tests are administered, these are time consuming (may take up to 3
hours) and not available in routine practice. A 7-minute screening battery exists which
incorporates four sub-sets testing memory, verbal fluency, orientation to time and clock
drawing. This test is however hampered by the need for special equipment and training, and
may not be cross-culturally valid. It was also not specifically designed to detect impairment
of executive function32.
To detect executive cognitive impairment in a busy clinical setting such as this one we
proposed a 5 minute test battery that is easy to score, can be administered with minimal
training and requires no equipment besides a pen and scoring sheet. However the patient is
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required to be fluent in English and must have adequate eyesight. We termed this test the
Bedside Executive Screening Tool (BEST).
The proposed BEST (appendix B) comprises the following 5 different tasks:
Task 1 – Registration/attention
Three word registration affirms that a patient is able to attend (concentrate) on a task. If a
patient cannot complete this task, then they will be unable to perform further cognitive
testing. This also affords the opportunity to learn the words that will test episodic memory
function (task number 4). Episodic memory refers to the laying down and recall of a specific
event or details.
Task 2 – Executive clock drawing task (CLOX1)
The CLOX is an executive task based on clock drawing. The patient is presented with a blank
piece of paper and given the instruction “draw me a clock that says 1:45. Set the numbers
and hands on the face so that a child could read them”. The instructions may be repeated if
necessary however once they begin the task no further assistance from the examiner is
permitted. CLOX is divided into parts 1 and 2 which discriminates the executive control of
clock drawing from actual clock drawing itself. For the BEST only part 1 (CLOX1) is used as
this part is dedicated to determining executive function. A clock is well recognised by most
individuals and is not biased by culture32. Clock drawing is also able to overcome language
barriers6. A score of 10 out of 15 represents the 5th percentile for young adults9.
Task 3 – Verbal fluency
Verbal fluency tests the patient’s ability to manipulate semantic memory (the knowledge of
facts and concepts). The patient is requested to name as many animals that walk on four
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legs in a 1 minute period. Selection of the category of four-legged animals was made to
minimise cultural and educational bias. Normative data for the naming of animals shows
that 90% of people with 9 or more years of education will name 13 or more animals, while
those with less than 9 years education name 12 or more animals14.
Task 4 – Three item delayed recall
Recalling the three words named in task 1 is a test of episodic memory functioning. This
does not test executive function but has been included in the battery with the goal of
adding to the value of the BEST as an evaluating tool of general cognition, and thus affording
an opportunity for appropriate dementia referral and management. There is evidence that
combining a clock drawing test and a 3 word recall test (the mini-cog) are helpful in bedside
screening of dementia13.
Task 5 – Problem solving
This is a complex problem solving task that tests the ability of the patient to formulate an
efficient problem solving strategy. “I have 18 books that need to be packed on 2 shelves.
One of the shelves needs to have twice as many books on it as the other shelf. How many
books must I put on each shelf?” It is not unreasonable to ask a patient, who may
potentially be required to understand and implement a complicated management regimen,
to solve this reasonable problem to reaffirm that they understand the complexities of
managing their illness. For example if a patient is a diabetic, they may be required to
administer therapeutic regimens such as multiple varied insulin dosing as well as the other
complicated lifestyle requirements that are required for successful medical management.
This task is particularly relevant to patients on a biphasic insulin regimen where doses are
divided into two thirds in the morning and one third in the evening.
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Executive impairment was diagnosed as present in a patient who demonstrated two or
more of the following criteria:
1. CLOX1 score of <10
2. Naming ≤12 animals (or ≤11 if patients had completed fewer than 9 years of
education)
3. Inability to solve the problem correctly
2.3 AIMS
 To ascertain the incidence of executive dysfunction in patients attending a tertiary
diabetic clinic.
 To correlate executive impairment with glycaemic control, target organ damage,
patient report adherence and prescribed medications.
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2.4 METHODS
2.4.1 STUDY DESIGN
A prospective clinical study
2.4.2 STUDY POPULATION
People with type 2 diabetes attending the tertiary referral Diabetic Clinic at Groote Schuur
Hospital, Cape Town, were invited to participate in the study during their usual clinic visits
between 1 March 2006 and 31 June 2006. Groote Schuur Hospital is a university teaching
hospital serving an open population of approximately 2.9 million persons. The clinic
provides care for people with diabetes from lower socioeconomic income groups (more
affluent patients with health insurance tend to seek medical care in the private sector), with
poor disease control and/or established target organ damage.
Exclusion criteria: (rationale for exclusion)
1. Patients not fluent in English (These patients would be disadvantaged with regards to
the verbal fluency task).
2. Visual impairment to the degree that it precluded the completion of the clock drawing
task.
3. Laboratory tested blood glucose recorded on the day of their clinic visit of less than 4
or greater than 15mmol/l (Extremes of glucose may be responsible for
transient/reversible cognitive dysfunction and thus bias result interpretation).
4. Prior cerebrovascular accident.
5. Patients known to suffer from depression.
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2.4.3 MEASUREMENT TOOLS
1. Completion of the BEST (appendix B), administered according to a standardised
proforma by either the attending clinician or a research nursing assistant.
2. A copy of the routinely completed diabetic clinic clerking proforma (appendix C).
Data collected from this source included:
- Age
- Patient reported dietary and medication adherence
- Target organ damage: this comprised microvascular (retinopathy,
nephropathy, neuropathy) and macrovascular (ischaemic heart disease,
peripheral vascular disease) complications
- Prescribed medications
3. Glycated haemoglobin and random laboratory glucose measurement on the day of
assessment.
2.5 ETHICAL CONSIDERATIONS
 The only non-routine intervention that a study participant underwent was
completion of the BEST battery, which takes only 5 minutes to administer. All
other data collected was obtained from the diabetic clinic proforma clerking sheet
on which patient details are routinely recorded (appendix C).
 All patients provided written informed consent which was obtained by the
administering physician (appendix D).
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 No financial compensation was available for either the participant or the physician
collecting the data.
 All patient information was kept strictly confidential.
 What were the implications of discovering cognitive impairments in any of the
study population?
Treatment of executive dysfunction where there was preliminary evidence of
benefit at the time of the study included:13
1. Consideration of statin use if clinically indicated, as there is evidence that
this may improve cognitive function.
2. The use of low dose aspirin as an antithrombotic medication where clinically
indicated.
3. Exercise.
All of the above measures are current management goals for all patients attending the
diabetic clinic.
When behavioural, social, psychiatric problems or other medical problems were discovered
that could not be appropriately managed in the diabetic clinic setting the additional
resources of the Memory, Geriatric or community Psychiatric services were made use of on
a referral basis. These clinics are routine services available to all referred patients.
The study was conducted in accordance with the principles of good clinical practice
enunciated in the World Medical Association Declaration of Helsinki 2000 (clarified 2002
and 2004)33.
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2.6 STATISTICAL METHODS
Data was entered into a database, coded, and then analysed. The Student’s T-test was used
to determine the statistical difference between the means of age, years of education and
total number of target organs affected by diabetes. The Chi square test was employed to
assess the statistical difference between medication and dietary adherence as well as
difference in drug usage between patients with and without executive impairment. Fisher’s
exact test was used to assess the statistical differences in diabetic control between those
with and without executive impairment.
2.7 FUNDING
The only implicated costs of the study were those of copying the data recording sheets and
this was born by the affiliated departments and individuals.
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2.8 RESULTS
Of the 107 patients recruited, 98 consented to participation in the study.
DEMOGRAPHIC DATA
 Women comprised 61 patients (62%), whilst there were 37 males (38%)
 Mean age was 57.7 years, standard deviation (SD) 10.4 with a range of 31-85
years.
 The mean education level was 8.2 years (SD 2.5) with a range of 3-16.
Figure 3: Distribution of age of screened type 2 diabetic patients
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Figure 4: Distribution of years of education in screened type 2 diabetic patients
COGNITIVE TEST RESULTS
1. Three word registration: - Participants scored a mean of 2.95 words (SD 0.2), ranging
between 2-3 words with no participant registering less than 2 words.
2. Executive Clock-drawing task part 1(CLOX1): - This task yielded a mean score of 11.0
(SD 3.2) with 15 being the maximum achievable score possible. Scores ranged from 2
to 15. Twenty-two (22%) participants scored less than 10 indicating possible executive
impairment.
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Figure 5: Examples of poor scoring clocks as drawn by screened type 2 diabetics34
Figure 6: Distribution of clock drawing scores in screened type 2 diabetic patients
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3. Verbal fluency: - The mean number of animals named was 10.3 (SD 3.2), the range was
wide with between 4 to 27 animals being named. Seventy of the participants (71%)
named 12 or less animals.
Figure 7: Distribution of verbal fluency scores for screened type 2 diabetic patients
4. Delayed three word recall: - Mean number of words recalled was 2.3 (SD 0.8), range
between 0 to 3 words. Twenty of the participants (20%) recalled less than two words.
5. Book problem solving task: - Only 46 participants (47%) solved this problem correctly,
with 28 patients making the similar mistake and giving the answer as “9 and 9”.
Verbal fluency for 4-legged animals named in one minute by Diabetics
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6. Executive function impairment : - Fifty one of the 98 participants (52%) failed to
complete two or more tasks (task no. 2, 3, and 5) meeting the criteria of executive
impairment.
7. Min-cog: - This was abnormal in 15 out of the 51 participants (29%) with executive
impairment and only 2 out of the 47 participants (4%) without executive impairment.
Executive impairment was strongly associated with an impaired Mini-cog (p=0.001)
with an odds ratio of 9.4 (95% confidence interval 2.0-43.7).
GLYCAEMIC CONTROL
 Mean HbA1c was 8.8% (SD 1.6) with values ranging from 6.0% to 14.0%
 Eighty four of the 98 screened participants were found to have inadequate glycaemic
control (HbA1c ≥7%) and only 14 had adequate control.
 A total of 51 participants demonstrated executive impairment, 48 of these 51
participants with executive impairment (94%) had inadequate glycaemic control,
whilst only 3 participants with executive impairment (6%) had adequate glycaemic
control.
 Patients with executive function impairment were more likely to have poor diabetic
control (p=0.019). Odds ratio: 4.9 (95% confidence interval 1.3-18.8).
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Table 3: Glycaemic control in relation to presence of executive impairment
EXECUTIVE IMPAIRMENT
PRESENT
(n=51)
EXECUTIVE IMPAIRMENT
ABSENT
(n=47)
HbA1c <7.0% 3 (6%) 11 (23%) P=0.019
HbA1c ≥7.0% 48 (94%) 36 (77%) NS
 Education level and glycaemic control – For participants with adequate glyacemic
control (HbA1c <7%) there was no significant difference in years of education
between those with and without executive impairment. However, in participants
who did not have glycaemic control (HbA1c ≥7%) there was a significant difference in
years of education with a mean of 9.5 years (SD 2.9) in those without executive
impairment and only 8.0 years (SD 2.1) in those with executive impairment
(p=0.013).
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Table 4: Years of education in relation to glycaemic control
EXECUTIVE IMPAIRMENT
PRESENT
(years of education)
EXECUTIVE IMPAIRMENT
ABSENT
(years of education)
HbA1c <7.0% 8.7±1.2 9.8±3.3 NS
HbA1c ≥7.0% 8.0±2.1 9.5±2.9 p=0.013
 Mini-cog test scores and glycaemic control – there was no significant difference in
mini-cog test scores in patients with poor glycaemic control compared to those with
good control (p=0.43).
Table 5: Mini-Cog scores in relation to glycaemic control
NORMAL MINI-COG
(n=81)
ABNORMAL
MINI-COG
(n=17)
HbA1c <7.0% 9 (11%) 3 (18%) p=0.43/NS
HbA1c ≥7.0% 72 (89%) 14 (82%)
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PATIENT REPORTED ADHERENCE
1. Dietary reported adherence: - 47 participants (49%) reported adherence, of these 20
(43%) were without executive impairment and 27 (53%) fulfilled the criteria for
executive impairment. A total of 49 (50%) were self-reported as non-adherence. Of
these non-adherence patients, 27 (55%) patients were free of executive impairment
whilst 22 (45%) were impaired. In 2 participants dietary adherence was not assessed.
2. Adherence to medication: - 72 (73%) patients reported adherence to medications. Of
these patients there was an equal distribution of executive impairment, 36 (50%)
participants meeting requirements for executive function impairment and 36 (50%)
not being impaired.
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Table 6: Patient reported adherence to diet and medication
EXECUTIVE
IMPAIRMENT
PRESENT (n=51)
EXECUTIVE
IMPAIRMENT
ABSENT* (n=47)
DIET
Adherence 27 20 NS
Non-adherence 22 27 p=0.30
MEDICATION NS
Adherence 36 36 NS
Non-adherence 13 11 p=0.90
*In two patients dietary adherence was not known
TARGET ORGAN DAMAGE
Target organ damage included retinopathy, nephropathy, neuropathy, ischaemic heart
disease and peripheral vascular complications as recorded on the diabetic clerking proforma
with a maximum possible total of five. There was no significant difference between the
mean number of target organs damaged 1.7 (SD 1.2) in those participants with executive
impairment and 1.4 (SD 1.3) those without (p=0.79).
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PRESCRIBED MEDICATIONS
Usage of metformin, sulphonylureas, insulin, aspirin and statins was not significantly
different between those participants with and without executive impairment. There was a
significant relationship between the use of an angiotensin converting enzyme (ACE) inhibitor
and the absence of executive impairment, this class of drug was used by a total of 64 (66%)
participants. Usage was 28 out of 51 (55%) participants who had executive impairment and
36 out of 47 (77%) participants who had no executive impairment (p=0.027). Medication
data was missing from one patient.
Table 7: Prescribed medications with relation to incidence of executive impairment
Medication
prescribed
Executive
impairment present
(n=51)
Executive
impairment absent
(n=47)
Metformin 32 (63%) 32 (68%) NS
Sulphonylureas 16 (31%) 18 (38%) NS
Insulin 39 (76%) 37 (79%) NS
Aspirin 32 (63%) 36 (77%) NS
Statin 17 (33%) 18 (38%) NS
ACE inhibitor 28 (55%) 36 (77%) p=0.027
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3. DISCUSSION
Both the chronic diseases of type 2 diabetes mellitus and cognitive impairment are
increasing in incidence. This is compounded by a generally ageing population worldwide and
warrants a closer look at their association24. The diabetic clinician cannot afford to be
ignorant to the possibility of executive impairment in his/her patients.
This study population was in keeping with diabetic populations seen at many other type 2
diabetic clinics throughout the world, burdened predominantly by patients with poor
glycaemic control and/or target organ damage.
The achievement of individualised glycaemic targets is challenging for people with diabetes.
Diabetes requires complex self-management i.e. glucose monitoring, meal planning and
complex medication regimen adherence. Patients also need to be able to manage acute
conditions, such as hypoglycaemia as well as other more chronic associated conditions e.g.
hypertension12. Thus impairment of executive functioning jeopardises glycaemic control.
Patients with executive dysfunction are at an increased risk of:
 Omission of medications
 Omission of meals
 Incorrect dosing
 Incorrect timing of dosing12
Hence the finding in this small study that poor glycaemic control (HbA1c ≥7%) was
significantly associated with executive function impairment as detected by simple clinical
testing is notable, yet not surprising.
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Whether this impairment is another form of target organ damage or rather the cause of
poor control, is not clear. Considering the close relationships, both are probably true with an
intertwined cause and effect relationship. A vicious circle exists where executive impairment
hampers glycaemic control which in turn makes the patient more vulnerable to further
cognitive insults etc.
Sinclair et al (after adjusting for age and sex) demonstrated the following in diabetic
individuals with poor cognitive scores:-
 Patients were less likely to undertake self-management
 Patients were less likely to attend a specialist diabetic clinic
 Patients were more likely to have been hospitalised in the past year
 Patients were more likely to require help with self-care
 Patients were more likely to be living in an institution
 Patients had impaired scores on tests of activities of daily living (ADL’s)8.
Thus in these individuals the need for informal caregiver input is vital and increases8. Indeed
impaired executive functioning may have a more profound impact on a patients’ autonomy
than poor memory1.
Physicians routinely screen for target organ damage and other cardiovascular risk factors,
but not for cognitive dysfunction. Health care providers are generally unaware of the
problem12. The clinician cannot rely on self-report as patients with executive impairment are
less likely to self-report, perhaps due to impaired insight. This study confirms this with no
difference in reported adherence between participants with and without executive
impairment. This is a particular problem in those patients living alone. The under-
40
recognition of executive impairment places the patient in danger of receiving inappropriate
less aggressive care, whereas such patients warrant more specialist input rather than less8.
Demonstrating cognitive dysfunction reaffirms current clinical practice which should aim to
provide optimal diabetic management, providing the clinician with an understanding of the
cognitive limitations a complex therapeutic regimen may pose.
Traditional bedside /clinic cognitive testing has used the MMSE, which does not adequately
test for executive function and may lead to further under-recognition3. The alternatives are
complicated and time consuming batteries of tests which are not practical in busy clinics.
The BEST takes less than five minutes to complete, it is easy to score and seems acceptable
to both patients and administering clinicians. The BEST proved to be effective in screening
for executive impairment as it was able to confirm the suspected increased incidence of
executive impairment in type 2 diabetics as demonstrated by other studies. Impairment of
the executive components of the BEST correlated with impaired glycaemic control while the
delayed recall component plus clock drawing task in the BEST (the mini-cog component) did
not. The mini-cog is recognised as an acceptable screening tool at a population level for
dementia35. The BEST was therefore more associated with impaired glycaemic control than
a dementia screening tool in this study.
Not only did the study look at the association between HBA1C and executive function, but
also looked for any other possible correlations between executive impairment, target organ
damage, adherence and/or medications prescribed. None of these yielded any major
significant associations. However, there did appear to be an association of some significance
between the absence of executive impairment and the use of ACE inhibitors. ACE inhibitors
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appeared to play a possible protective role, perhaps this would be more pronounced in a
study with a larger cohort of patients.
Previous studies have shown a positive association between the use of anti-hypertensive
agents and cognitive impairment in type 2 diabetes30. However these agents most likely
serve as a surrogate marker for hypertension, and the effects are probably due to the
hypertension and not a side effect of treatment. There is little evidence of cognitive
impairment or decline associated with the use of anti-hypertensive agents except for
treatment induced hypotension in the elderly30. To the contrary this study hints at a possible
protective role of these agents, specifically ACE inhibitors. Vascular risk factors in diabetics
are diminished by lowering blood pressure19. In the Systolic Hypertension in Europe trial
(Syst-Eur trial) active treatment of hypertension was shown to decrease the incidence of
dementia by 50% after two years of follow-up36. ACE inhibitors are known to be protective
for other forms of diabetic target organ damage, such as diabetic nephropathy.
This association may also serve to signify the association between hypertension and
cognitive impairment, particularly a sub-cortical frontal vascular pattern. A significant
association exists between diabetes and hypertension although there is evidence of specific
deficits associated with type 2 diabetes independent of hypertension30.
The lack of a significant association with these co-morbidities strengthens the finding that
hyperglycaemia itself is related to executive impairment and is not merely being
misrepresented by these confounding co-morbid conditions. A similar finding was reported
by Sinclair et al. where eight forms of target organ damage (nephropathy, peripheral
neuropathy, history of depression, ischaemic heart disease, hypertension, autonomic
neuropathy, diabetic foot and stroke) were considered however only previous stoke and
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established autonomic neuropathy were associated with lower MMSE scores8. This study
excluded patients with known stroke.
Another interesting observation made was that those with executive impairment and
inadequate glycaemic control had a lower mean number of years of education as compared
to those without impairment with inadequate glycaemic control. Executive functioning
comprises a set of acquired complex skills2. Education seems to assist in the acquisition of
these skills and increases ones cognitive reserve, thus buffering against future possible
cognitive decline14. Hence this finding illustrates that patients with a lower mean number of
years of education are more vulnerable to cognitive insults manifesting in clinically
significant executive impairment.
Why screen for executive impairment? As discussed above patients detected early with
executive function impairment may benefit from individualized goals, management review,
caregiver support, psychosocial interventions and more intense specialist input8. These
interventions would serve to improve their future glycaemic control. There are still no
established specific treatments or measures to prevent or ameliorate executive impairment.
However early findings suggest benefit on cognition to be gained through improving
glycaemic control and thus preventing a downward spiral of further executive impairment
and decreasing medication adherence30. Other treatment strategies suggest avoidance and
treatment of cardiovascular risk factors28. In the PROSPER trial pravastatin decreased
dementia rates and improved scores on the MMSE and CLOX1. Some have suggested benefit
from the appropriate use of anti-cholinesterase drugs such as Donepezil8. Physical activity
(aerobic fitness) is recommended to improve cognition as well as play a preventative role in
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decline. These effects are mediated through improved cerebral perfusion/oxygenation,
decreased inflammatory mediators and decreased levels of stress hormones1.
Weaknesses of this study are largely based on the small number of patients screened and
the observational nature of the study. Data gathered was limited due to the time
constraints of a busy diabetic clinic and could have included instrumental activities of daily
living and additional cognitive testing such as trail making tests and the mini-mental state
examination. This weakness is however also a strength since the BEST performed well in a
real life clinical setting.
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4. CONCLUSION
Executive functioning is vital to the type 2 diabetic patients’ ability to self-manage their
disease complex and to achieve glycaemic targets. There is an increased incidence of
executive function impairment in type 2 diabetics. This small real life clinical study
demonstrates a meaningful relationship between poor glycaemic control (HbA1c ≥7.0%) and
executive impairment. Poor glycaemic control in these patients may be both the cause and
effect of executive impairment.
Diabetic clinicians may largely be unaware of executive impairment in their patients due to a
lack of screening. Traditional screening tools are either insensitive (MMSE) or impractical,
time consuming batteries. Our tool, the BEST, is easy to both administer and score and takes
less than five minutes.
Education plays a protective role against future cognitive decline and this seems to also
apply specifically to the executive domain. The use of ACE inhibitors may also prove to be
protective against executive impairment, possibly preventing another form of target organ
damage.
Executive functioning is important in all type 2 diabetics and regular screening, ideally
annually, is recommended, as well as screening for other associated cardiovascular risk
factors and target organ damage, especially in those patients with poor or declining
glycaemic control.
45
5. RECOMMENDATIONS
Findings in this study are an impetus to conduct a study with a larger population group. This
study could be extended to implementing interventions in those found to have executive
impairment, specifically targeting executive function with a view to following HbA1c levels
for improvement.
However I feel that already with this small study and the reviewed literature there is enough
evidence and motivation for clinicians to start screening for executive impairment in type 2
diabetics.
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Conventional management of type 2 diabetes relies heavily 
on the principles of self-management. This is in essence 
a series of complex goal-directed behaviours required for 
lifestyle and behavioural changes as well as adherence to 
pharmacological interventions aimed at managing glycaemic 
control, hypertension, lipid profiles, weight and physical 
activity. Successful disease management is dependent on the 
patient’s ability to execute these interventions and maintain 
lifelong adherence.  Not only do people with type 2 diabetes 
have a greater rate of decline in cognitive functioning and 
risk of future dementia than people without diabetes,1,2 but 
the cognitive impairment is associated with poor diabetes 
control.3,4
The executive functioning domain of cognition is important 
in allowing the development of adaptive strategies and 
the ability of an individual to modify his/her behaviour 
in response to dynamic task requirements.5 Impairment of 
executive function has been clinically linked with functional 
impairment, poor medication adherence, increased level of 
care needed and even patient resistance to care.6-8 Executive 
impairment divorces ability from implementation.5 Type 2 
diabetes has been shown to be associated with impairment in 
executive cognitive functioning.6,9,10 This is attributed to frontal-
subcortical dysfunction due to microvascular disease.5,10
We sought to determine whether executive impairment as 
detected by a simple battery of beside executive function tests 
was associated with inadequate glycaemic control as defined 
by an HBA1c level ≥7%.
Patients and methods
People with type 2 diabetes attending the tertiary referral 
Diabetic Clinic at Groote Schuur Hospital, Cape Town, were 
invited to participate in the study during their usual clinic 
visits between 1 March 2006 and 31 June 2006. Groote Schuur 
Hospital is a university teaching hospital serving an open 
population of approximately 2.9 million persons. The clinic 
provides care for people with diabetes from lower socio-
economic income groups (more affluent patients with health 
insurance tend to seek medical care in the private sector), with 
poor disease control and/or established target organ damage. 
Study exclusion criteria included poor fluency in the English 
language, visual or hearing impairment, current management 
with an antidepressant, and/or precognitive evaluation blood 
glucose <4 mmol/l or >15 mmol/l on the day of assessment.
Executive cognitive impairment detected by simple bedside 
testing is associated with poor glycaemic control in type 2 
diabetes
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Aims. Cognitive impairment in people with type 2 diabetes 
is a barrier to successful disease management. We sought to 
determine whether impaired executive function as detected by 
a battery of simple bedside cognitive tests of executive function 
was associated with inadequate glycaemic control.
Methods. People with type 2 diabetes attending a tertiary 
referral diabetic clinic who consented to participate in the 
study underwent a brief battery of cognitive testing (the 
Bedside Executive Screening Test) designed to detect executive 
function impairment.  Glycaemic control was determined 
using blood glycated haemoglobin levels (HBA1c). Inadequate 
glycaemic control was defined as HBA1c ≥7%.
Results. Executive function impairment was detected in 51 
(52%) of the 98 study participants. The presence of executive 
function impairment was significantly associated with poor 
glycaemic control (HBA1c ≥7%) (odds ratio 4.9, 95% confidence 
interval 1.3 - 18.8, p=0.019). There were no significant 
differences between patients with and without executive 
function impairment with regard to age, target organ damage, 
patient reported adherence, and hypoglycaemic therapy.  
Patients with a lower level of education were more likely to 
demonstrate executive impairment when glycaemic control 
was poor (p=0.013). 
Conclusions. Executive function impairment is common 
in a population of people with difficult-to-manage type 2 
diabetes. The presence of executive impairment is significantly 
associated with poor glycaemic control.
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Cognitive testing was performed using a battery we termed 
the Bedside Executive Screening Test (BEST). This comprised 
five parts:
• three item registration 
• three item delayed recall test 
•  executive clock drawing task part 1 (CLOX1): ‘draw me a clock 
that says 1:45. Put the numbers on the face so that a child could 
read them’11 
•  verbal fluency test: ‘name as many animals with 4 legs as you 
can think of in 1 minute’ 
•  problem solving task: ‘I have 18 books that I need to put on 2 
shelves. One of the shelves must have twice as many books on it as 
the other shelf. How many books must I put on each shelf?’
The latter three cognitive tests draw mainly on the cognitive 
domain of executive functioning.6,7 Abnormal tests were 
defined as: 
• CLOX1 score of <1011 
•  naming ≤12 animals (or ≤11 if patients had completed fewer 
than 9 years of education)12 
• inability to solve the problem correctly.
An assessment of executive impairment was made if patients 
had abnormal results for at least two of the three tests of 
executive functioning. The cognitive tests were administered 
according to a standardised proforma by either the attending 
clinician or a research nursing assistant. 
Clinical, demographic and laboratory characteristics were 
recorded at the time of assessment and included gender, 
age, level of education (in completed years), laboratory 
blood glucose and glycated haemoglobin level on the day 
of assessment, the presence or absence of microvascular 
(retinopathy, nephropathy, neuropathy) and macrovascular 
(ischaemic heart disease, peripheral vascular disease) 
complications, patient-reported dietary and medication 
adherence, and the various medications the patient reported 
using.
 All microvascular and macrovascular complications 
were defined according to our clinic protocol. A composite 
score of the three abovementioned microvascular and two 
abovementioned macrovascular complications was created.
Student’s t-test was used to determine the statistical 
difference between the means of age, years of education and 
total number of target organs damaged. The chi-square test 
was used to assess the statistical difference between dietary 
and medication adherence as well as the difference in drug 
use between patients with and without executive impairment. 
Fisher’s exact test was used to assess the statistical differences 
in diabetic control between those with and without executive 
impairment. The institutional Ethics Committee approved the 
study protocol and all study subjects gave written informed 
consent. 
Results
Of the one hundred and seven patients recruited, 98 consented 
to participation in the study. Women comprised 61 patients 
(62%). The mean age was 57.7 years (standard deviation (SD) 
10.4) (range 31 - 85 years), and the mean education level was 
8.2 years (SD 2.5) (range 3 - 16 years). Executive function 
impairment was present in 51 (52%) of the participants. For 
the clock drawing task (CLOX1) the mean score was 11.0 (SD 
3.2) (range 2 - 15), with 22 (22%) of patients scoring below 10 
(Fig. 1). The mean verbal fluency score was 10.3 (SD 3.2) (range 
4 - 27), with 70 patients (71%) naming fewer than 12 animals. 
Only 46 patients (47%) answered the book problem correctly, 
with 28 patients giving the answer as ‘9 and 9’.
Table I shows the demographic characteristics, diabetic 
control, reported adherence, target organ damage and drug 
usage differences between the study patients with and without 
executive impairment. 
Patients with executive impairment were more likely to have 
poor diabetic control (odds ratio 4.9, 95% confidence interval 
1.3 - 18.8).
Discussion
Our study population, in keeping with many other diabetes 
clinics throughout the world, comprised predominantly people 
with type 2 diabetes with inadequate glycaemic control and/or 
target organ damage. Education is shown to affect executive 
function.12 In our study patients with lower levels of education 
appeared more vulnerable to executive impairment when 
glycaemic control was inadequate.
The achievement of individualised glycaemic targets is 
challenging for people with diabetes.13 The observation that the 
Fig. 1. Examples of abnormal clocks drawn by study participants 
demonstrating executive cognitive impairment. CLOX score is 
indicated.
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presence of executive cognitive impairment was significantly 
associated with poor glycaemic control in this small study was 
therefore notable and potentially adds another dimension to 
the already complex interaction between health provider and 
patient.  Indeed, people with executive functioning deficits 
as detected by cognitive testing may require alternative 
management strategies to enhance disease control. 
Traditional bedside/clinic cognitive testing has used the 
Mini Mental State Examination, which does not adequately 
test for executive cognitive impairment, with poor 
sensitivity, especially in early disease.14 Formal batteries of 
neuropsychological tests are time consuming (taking up to 
3 hours to administer) and may not be available or practical 
in routine clinical practice. Even a validated test such as the 
Executive Interview takes 15 minutes to administer, too long 
for the busy diabetic clinic.15 Our bedside battery takes 5 
minutes or less to administer and requires minimal training 
beyond the scoring of the clock drawing task (CLOX1).11 
Clinicians are largely unaware that executive impairment 
may occur frequently in a variety of medical conditions, 
including diabetes.6 The findings of this study should be 
repeated in a larger study and may well provide impetus to 
perform a brief cognitive screening battery routinely – we 
propose the use of a battery such as ours. 
Specific strategies required to improve control in people 
with type 2 diabetes and executive impairment remain to 
be determined, but awareness and increased recognition 
of executive impairment is currently the greatest clinical 
challenge.
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Table I. Differences in demographic characteristics, diabetic control, reported adherence, target organ damage and drug usage 
between patients with and without executive impairment
                    Executive impairment 
                  Absent (N=47)            Present (N=51) 
Age (mean±SD)      56.2±10.0   59±10.7  NS
Years of education (mean±SD) 
HBA1c <7.0%      9.8±3.3   8.7±1.2  NS
HBA1c ≥7.0%       9.5±2.9   8.0±2.1  p=0.013
Diabetic control (N (%))   
HBA1c <7.0%      11 (23%)   3 (6%)  p=0.019
HBA1c ≥7.0%      36 (77%)   48 (94%) 
Patient reported adherence (N (%))   
Dietary       20 (43%)   27 (53%)*  NS
Medication      36 (77%)   36 (71%)  NS
Mean No. of target organs damaged (±SD)   1.4±1.3   1.7±1.2  NS
Drugs used (N (%))   
Metformin      32 (68%)   32 (63%)  NS
Sulphonylureas      18 (38%)   16 (31%)  NS
Insulin       37 (79%)   39 (76%)  NS
Aspirin      36 (77%)   32 (63%)  NS
Statin       18 (38%)   17 (33%)  NS
ACE inhibitors      36 (77%)   28 (71%)  p=0.041
*In 2 patients dietary adherence was unknown.
NS = not significant.
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APPENDIX B
The Bedside Executive Screening Test (BEST)
Age of patient:
Level of education of patient:
Test tasks
1. Three word registration: “I want you to remember 3 things for me: a pen, an apple,
and a table” “Please tell me the three items” ”Good, remember them I will ask you
again later” Score out of 3.
2. Clock drawing test: “draw me a clock that says 1:45. Put the numbers on the face
so that a child could read them” Score out of 15 as per the CLOX1 scoring
method. Do not help patient any further once they start the task. Use back of this
sheet for the task.
3. Verbal fluency: 4-legged animals named in one minute: “name as many animals
that walk on 4 legs as you can think of in one minute.” Score one point per animal
named correctly.
4. Delayed three word recall: “please could you tell me the three items I asked you to
remember earlier.” Score out of three.
5. Problem solving task:” I am going to ask you to solve a problem for me: I have 18
books that I need to put on 2 shelves. One of the shelves needs to have twice as many
books on it as the other shelf. How many books must I put on each shelf?” Repeat the
clinical problem once. Record the answer given by the patient.
Scoring system:
1. Attention /3
2. Clock drawing (see CLOX1 scoring) /15
3. Verbal fluency one point per animal
4. Delay recall /3
5. Problem solving task solved correctly yes/no answer given=
Executive dysfunction present if two or more of:
 Clock drawing score <10/15
 Scores ≤ 12 animals on verbal fluency test if has ≥ 9 years of education or
scores ≤ 11 animals on verbal fluency if has < 9 years education.
 Cannot correctly solve bookshelf packing problem.
Scoring system for CLOX1
Point value
 Does figure resemble a clock? 1
 Outer circle present? 1
 Diameter >2.5cm 1
 All numbers inside circle 1
 12,6,3,9 placed first 1
 Spacing intact (symmetry on either side of the
 12-6 axis?) If yes, skip next. 2
 IF spacing errors are present, are there signs of
 Correction or erasure? 1
 Only Arabic numerals? 1
 Only numbers 1-12 amoung the Arabic numerals? 1
 Sequence 1-12 intact? No omission or intrusions? 1
 Only two hands present? 1
 All hands represented as arrows? 1
 Hour hand between 1 and 2 o’clock 1
 Minute hand longer than hour hands 1
 None of the following 1) “hand pointing to 4 or 5” 1
2) “1:45” present
3) Intrusions from “hand” or “face” present
4) Any letters, words or pictures

APPENDIX D
Patient Information and Consent Form
Study: The incidence of executive cognitive dysfunction detected by a Bedside Executive Screening
Tool (BEST) in a cohort of type 2 diabetics attending a tertiary diabetic clinic.
Invitation to participate:
You are invited to take part in a study which we hope will enable us to detect changes in the way
that diabetic patients are able to plan and approach problem solving tasks.
Why have I been asked?
Patients attending their Diabetic Clinic visits at Groote Schuur Hospital will be asked to participate in
this study if they have type 2 diabetes, satisfactory eyesight and can speak English fluently.
What is the purpose of this study?
We hope to determine whether a short questionnaire comprising 5 tasks is able to detect problems
with the way diabetic patients are able to plan and solve tasks that require complex thinking. At
present we know that diabetes may impact on the functioning of the brain. We do not however
know how common this problem may be.
What will happen to me if I take part?
During your routine clinic visit the doctor will ask a series of 5 short tasks aimed at testing your
problem solving ability. These tasks should take no longer than 5 minutes to complete.
Are there any risks?
No, you will not be asked to take any additional medicines or to undergo any treatments for this
study. Taking part is strictly voluntary and your care in the Diabetic Clinic will not be affected by
whether or not you participate in the study.
What are the benefits of taking part?
Although the purpose of this study is to gather information so that we can develop an understanding
of how to manage diabetic patient’s care better, if any problems are found that cannot be dealt with
by the Diabetic doctor, referral to other specialist help is available as needed. This is the usual
practice in the Diabetic clinic.
Will my taking part be kept confidential?
Yes. Only the project researchers will know your details. You will never be identified as having taken
part as the conclusions will draw on information provided by all the participants in the study.
I confirm that I have understood the above information for the study and that I have had the
opportunity to ask questions.
I understand that my participation is voluntary and that I am free to withdraw at any time.I agree
to take part in the above study.
Printed patient name Date of patient signature Patient sign

